Loading clinical trials...
Loading clinical trials...
Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Alabama Research Center
Birmingham, Alabama, United States
Southeast Alabama Medical Center
Dothan, Alabama, United States
Providence Hospital
Mobile, Alabama, United States
Arizona Pulmonary Specialists LTD
Phoenix, Arizona, United States
Sharp Chula Vista Medical Center
Chula Vista, California, United States
Synergy Clinical Research Center
Escondido, California, United States
Novellus Research Sites
Fountain Valley, California, United States
Novellus Research Sites
Long Beach, California, United States
Modesto Clinical Research
Modesto, California, United States
Tri City Medical Center
Oceanside, California, United States
Start Date
November 1, 2008
Primary Completion Date
June 1, 2010
Completion Date
July 1, 2010
Last Updated
May 25, 2018
137
ACTUAL participants
NXL104/ceftazidime
DRUG
Imipenem/Cilastatin
DRUG
Lead Sponsor
Pfizer
NCT04876131
NCT05826990
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04335539